Clinical Trial Update: Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma (BASALT) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Brentuximab Vedotin as an alternative to autologous stem cell transplantation in relapsed/refractory classical Hodgkin's lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma
• Hodgkin Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Conditions: Hodgkin's Lymphoma | Phase 2 | Status: UNKNOWN